Kornimate/medical-research-clean huggingface dataset:
effectiveness of cc vs aerobic exercise for strengthening and improving qol in post stroke patients

Conditions: Stroke

Summary: to determine the effects of closed chain versus aerobic exercise for strengthening and improving quality of life in post stroke patients


Eligibility criteria:
inclusion criteria: * hemiplegic post stroke patients (either left or right side) * patients of both gender * age range in between 40 to 60 * patient with cognitive functioning exclusion criteria: * history of any cardiac problem * recurrent stroke * any kind of disability or amputated limb * neurological conditions like parkinsonism, epilepsy and * spinal cord injury. * any kind of fracture or dislocation history.
bioequivalence study of 6-mercaptopurine under fasting conditions

Conditions: Acute Lymphoblastic Leukemia

Summary: the objective of this study was to assess the bioequivalence of a potential generic 6-mercaptopurine 50 mg tablet formulation compared with glaxosmithkline purinethol® (mercaptopurine) 50-mg scored tablets following a single 50 mg oral dose administered in the fasted state.


Eligibility criteria:
inclusion criteria: * no clinically significant abnormal findings on physical examination, medical history, or clinical laboratory results. * must voluntarily consent. exclusion criteria: * must not have a known history of thiopurine methyltransferase deficiency or family history. * must not have a history of elevated uric acid or gout. * must not be currently using allopurinol.
low dye taping technique versus robert debre method on foot posture and range of motion in children with club foot.

Conditions: Club Foot

Summary: to check the effects of the low dye taping technique versus the robert debre method on foot posture and range of motion in children with club feet.

this study was a randomized clinical trial. it was carried out in the physiotherapy department of children hospital lahore,those patients were taken who had congenital clubfoot.40 patients were taken with the predetermined inclusive and exclusive criteria through non probability convenience sampling technique.all participants informed about the study,group a received low dye taping technique 2 times in a week for 6 weeks,while the group b received the robert debre methpod daily 30 minutes session for total 6 weeks.foot posture, range of motion and gait will be assessed by demiglio bensahel and pirani scoring system with the help of goniometer and compared the results.data analyzed by spss 25.0 statistical software. after checking the normality of data nonparametric tests applied to check the difference between and within the groups.

Eligibility criteria:
inclusion criteria: 1. (1month to 6months ). 2. children having idiopathic club foot 3. unilateral or bilateral 4. severity by dimeglio bensahel scale we include moderate ,severe and very severe feet exclusion criteria: 1. benign or non idiopathic. 2. an associated syndrome or neurological disease. 3. positional club foot. 4. those previously treated with another method in other hospitals. 5. children with systemic diseases. 6. juvenile arthritis.

Keywords: low dye taping robert debre tecnique
testosterone treatment in men with chronic kidney disease

Conditions: Hypogonadism, Male; Kidney Disease, Chronic

Summary: this study in being conducted in men who have low testosterone and chronic kidney disease. the investigators will evaluate the effects of an oral testosterone preparation, jatenzo, on testosterone levels and hemoglobin (red blood cells).

* purpose. the purpose of this research is to find out if jatenzo will help increase testosterone levels in men with hypogonadism and chronic kidney disease, determine if there is any improvement in testosterone levels, hemoglobin (red blood cells), muscle strength, lean mass and sexual function. * the dug will be daily for 6 months. study procedures. every 2-4 weeks, the study participant will come in person for a research visit. investigators will collect a blood sample at certain visits, do a brief physical exam, and obtain vital signs such as height, weight, blood pressure. the study also involves completing questionnaires, measuring body composition by a scan and testing muscle strength. the dose of jatenzo may be adjusted based on the testosterone levels.

Eligibility criteria:
inclusion criteria: * men between ages of 18-85 years of age * egfr 15-45 ml/min/1.73m2 by mdrd (modification of diet in renal disease) equation * subnormal total serum t concentrations (\<300 ng/dl) on two separate occasions in morning * symptoms of hypogonadism (as per endocrine society guidelines): low libido, erectile dysfunction, fatigue, irritability, depressed mood, poor concentration, increased body fat, decreased muscle bulk, reduced physical performance, sleep disturbance, loss of body hair (15) * normal iron stores as defined by serum ferritin ≥100 ng/ml and transferrin saturation (tsat) ≥20%. exclusion criteria: * use of trt currently or in the past 6 months, including use of over-the-counter androgen containing health supplements (e.g., dhea) * hematocrit \>48% (as per endocrine society guidelines)(15) * treatment with erythropoiesis stimulating agents (esa) * uncontrolled blood pressure (\>180/100 mm hg) * heart failure, class iii or iv * myocardial infarction, stroke, or heart surgery in the past 3 months * breast cancer * history of prostate cancer * prostate specific antigen (psa) \>4 ng/ml, unless prostate cancer has been ruled out by a urologist (documented in physician notes) * hiv or untreated hepatitis c * untreated, severe obstructive sleep apnea * initiated iron replacement in the last 3 months * deep venous thrombosis or pulmonary embolism in the last 3 months * recurrent (more than once) deep venous thrombosis or pulmonary embolism * use of warfarin * planning to have children in the next one year

Keywords: testosterone ckd
fertility preservation in young women with cancer

Conditions: Cancer; Fertility

Summary: the researchers aim to record the incidence, treatment and long term follow up of fertility preserving cancer treatment. both the oncological and fertility outcome are recorded. study population: all patients with a cancer for whom a fertility preserving cancer treatment is applied. the results of the study population are compared to young women undergoing standard cancer treatment.

cancer is the second leading cause of death during the reproductive years. the long term survival improves for most cancers, reaching 80% for pediatric cancer and more than 70% for cancers in adults between 20 and 49 years of age. early detection and improvements in cancer treatment contribute to these figures. as a result, quality of life of which preservation of fertility is one aspect, becomes more important. fertility may however be influenced by surgery and by the gonadotoxic effects of chemo and/or radiotherapy. therefore, fertility sparing treatments are offered to young patients in order to maintain the wish to conceive after cancer treatment. this however is associated with deviation of standard treatment and many different strategies are applied among different centers. in addition, there is a lack of studies investigating the oncological safety of these fertility sparing treatment protocols. the results of this study will enable us to better inform clinicians and patients on the efficacy of fertility sparing cancer treatment. objective: to record the incidence, treatment and long term follow up of fertility preserving cancer treatment. both the oncological and fertility outcome are recorded. study design: international multicentre prospective observational trial study population: all patients with a cancer for whom a fertility preserving cancer treatment is applied. the results of the study population are compared to young women undergoing standard cancer treatment. main study parameters/endpoints: registration of cancer diagnosis, treatment and outcome. both the oncologic and fertility outcome is registered. all patients receive fertility sparing cancer treatment on their specific request.

Eligibility criteria:
inclusion criteria: * young women who want to preserve their fertility during cancer treatment. patients need to give their signed and written informed consent to participate in the study. exclusion criteria: * mentally disabled or significantly altered mental status that would prohibit the understanding and giving of informed consent

Keywords: cancer fertility pregnancy chemotherapy radiotherapy long term follow up
glycemic impact on glioblastoma outcomes

Conditions: Glioblastoma Multiforme; Hyperglycemia

Summary: this pilot study aims to evaluate the feasibility of close glucose monitoring and management of patients (targeting fasting and pre-meal glucose of 4-7 mmol/l) using state-of-the-art flash glucose monitoring (fgm) technology. the glycemic intervention will be personalized based on individual blood glucose levels. although the glycemic interventions used in this study include standard medications and methods of glucose monitoring used for patients with diabetes, this pilot study will specifically evaluate the feasibility of using these approaches in patients with gbm, appreciating their additional medical, functional and social challenges.

the purpose of this pilot study is to determine the feasibility of using close monitoring and management of glucose levels in patients undergoing radiation and chemotherapy for glioblastoma. the glucose management will include the use of standard metformin a common treatment for patients with early type 2 diabetes that has also shown anti-tumor effects in gbm, and will be further personalized based on individual blood glucose levels. additional anti-hyperglycemic management will be provided at the discretion of the endocrinologist. close glucose monitoring will include flash glucose monitoring (fgm) with a device called an freestyle libre pro flash glucose monitoring system, finger-prick glucose measures (standard approach for patients with diabetes) and weekly blood tests (our current standard for patients with gbm). in addition to determining the feasibility of using these approaches, this pilot study will help identify the simplest and most effective approach of managing glucose levels in patients with gbm appreciating their additional medical, functional and social challenges.

Eligibility criteria:
inclusion criteria: * adult patients (\> 18 years old) with a new histologically-confirmed diagnosis of glioblastoma who are planned to receive a 6-week course of concurrent radiation and temozolomide * has evidence of random glucose of at least 7.8 mmol/l or fasting blood glucose of at least 6.1 mmol/l (meeting criteria for oral diabetic medications) * able to provide informed consent * able to understand and follow instructions regarding self-administered capillary glucose measurements exclusion criteria: * contraindication to mri with gadolinium * taking anti-hyperglycemic medications at the time of study eligibility screen * unable to participate in neurocognitive evaluation in english

Keywords: glucose monitoring
does body position influence pressure recording by high-resolution manometry ?

Conditions: Anal Incontinence or Constipation

Summary: the anorectal manometry is the gold standard in the evaluation of anorectal function. several techniques are currently used (balloons, perfused catheters) and are always performed in the supine position. few studies have reported the evaluation of sphincter function in the upright position, whereas symptoms of fecal incontinence occur in this position. recently developed, high-resolution manometry, thanks to its many mechanical sensors, allows topographic analysis and evaluation of anorectal function more acurate. in addition, the rigid nature of the probe should allow stability measures / recording, which is not possible with probes perfused catheters example. we therefore propose to compare anal sphincter pressure in supine and standing, measured in high-resolution manometry.


Eligibility criteria:
inclusion criteria: * man or woman over the age of 18 years * patient referred for endoscopic ultrasound and anal manometry anorectal hr-3d which is an indication of fecal incontinence or dyschesia exclusion criteria: * patient age 18 less * patient trust, guardianship, judicial protection * no written consent * lack of social insurance * history of anorectal surgery * a presence of anal stenosis * a setting evidence of anorectal lesion preventing the realization of the screening * motor disability preventing the realization of the anorectal manometry 3d hr-standing situation
establish tolerance in ms with peptide-coupled, peripheral blood mononuclear cells

Conditions: Multiple Sclerosis, Relapsing-Remitting

Summary: open-label, single center, phase i clinical trial to assess the safety, tolerability and preliminary efficacy and in vivo mechanisms of action of i.v. administration of autologous peripheral blood mononuclear cell (pbmc) chemically coupled with a cocktail containing seven immunodominant myelin peptides to which t cell responses are demonstrable in early rr ms patients.

open-label, single center, phase i dose-escalation study to assess the safety, tolerability and preliminary efficacy and in vivo mechanisms of action of a single infusion of autologous peripheral blood mononuclear cells chemically coupled with seven myelin peptides (mog1-20, mog35-55, mbp13-32, mbp83-99, mbp111-129, mbp146-170, and plp139-154) in multiple sclerosis patients who were off-treatment for standard therapies. neurological, magnetic resonance imaging, laboratory, and immunological examinations were performed to assess the safety, tolerability, and in vivo mechanisms of action of this regimen.

Eligibility criteria:
inclusion criteria: 1. between the ages of 18 and 55 years. 2. patients with relapsing-remitting (phase i/ii) or secondary progressive ms (phase i) according to published criteria 3. edss score between 1 and 5.5. 4. patients are off-treatment for standard therapies (interferon-beta, glatiramer acetate, natalizumab, mitoxantrone) 5. patients are able to provide written, informed consent prior to any testing under this protocol, including screening and baseline investigations that are not considered part of routine patient care. 6. disease duration ≤ 5 years (only phase ii) exclusion criteria: 1. diagnosis of secondary-progressive (phase ii) or primary-progressive ms, as defined by published diagnostic criteria. 2. abnormal screening/baseline blood tests exceeding any of the limits defined 3. pregnant or breast-feeding female. 4. history or signs of immunodeficiency. 5. concurrent clinically significant (as determined by the investigators) cardiac, immunological, pulmonary, neurological, renal or other major disease. 6. splenectomy 7. history of hiv or positive hiv antibody testing 8. serology indicating active hepatitis b or c infection. 9. patients with cognitive impairments who are unable to provide written, informed consent prior to any testing under this protocol, including screening and baseline investigations that are not considered part of routine patient care
optimizing the radiological selection and transfer model in stroke patients presenting 6-24h after onset (vesta study)

Conditions: Stroke, Ischemic

Summary: we aim to optimize the radiological selection and the transfer model in patients with a 6-24h stroke for a fairer and broader access to a reperfusion treatment. the specific objectives are: 1. to confirm that the selection of patients for reperfusion therapies in the late window is safe by applying the same clinical and imaging criteria recommended by clinical guidelines for the early window treatment selection. 2. to evaluate the performance of non-contrast ct by applying immediate post-processing software for the selection of patients for reperfusion treatment in the late window. 3. to analyze the prehospital and arrival variables at the primary stroke center to generate decision trees that optimize the transfer decision in patients with activation of the stroke code in \>6h from the onset of symptoms. methodology: study based on a mandatory, prospective, multicenter registry (cicat registry) consisting of two phases 1. retrospective analysis with a detailed evaluation of the images of the included patients and generation of "machine learning" models that accurately predict the probability of receiving reperfusion treatment in the late window. 2. validation of the models in a prospective study. clinical, radiological and transport variables will be studied. response variables: rate of patients receiving reperfusion treatment in the late window, functional prognosis at 90 days, hemorrhagic transformation, and mortality.


Eligibility criteria:
* substudy 1. optimization of imaging selection methods for selecting stroke patients for reperfusion treatment in the extended window. - inclusion criteria: consecutive patients registered in the cicat registry between the years 2019 and 2021 with a stroke who meet the following criteria 1. age older than 18 years, 2. diagnosis of acute cerebral infarction, 3. more than six hours of evolution or uncertain chronology of symptoms, 4. absence of disability prior to stroke (modified rankin score 0-2), 5. nihss score\>5, 6. neuroimaging study including at least one non-contrast cranial ct scan within 60 minutes of arrival at the hospital center. * substudy 2. optimization of circuits and transfer model in patients with stroke in the extended window of treatment. * inclusion criteria: selection of consecutive, prospective patients to be included in the cicat registry between january 2023 and march 2024 with stroke meeting the following criteria: 1. age over 18 years, 2. suspicion of acute cerebral infarction, 3. more than six hours of evolution or uncertain chronology of symptoms, 4. absence of pre-stroke disability (modified rankin score 0-2), 5. nihss score greater than 5.
effects of learning and food form on intake in humans

Conditions: Obesity

Summary: due to the rising incidence of obesity, much emphasis has been placed on identifying mechanisms of increased energy intake. at this point, the mechanisms responsible for the recent increase in obesity prevalence have not been thoroughly examined. pre-ingestive influences, such as cognitive factors, may play a larger role in creating an energy surplus than previously thought. expectations about the satiating effect of a food may override the post-ingestive influences in dictating further consumption. in addition, obese individuals may exhibit a decreased compensatory response to foods as compared to lean individuals. understanding the effects of energy content, food form, and learning on satiation, satiety, and energy intake will allow for a greater understanding of the mechanisms of energy imbalance as a whole. food choice is dictated by sensory properties and post-ingestive effects. by utilizing foods with similar sensory properties, the acquired knowledge derived from ingesting these foods can be monitored by analyzing subsequent intake at the same meal and at subsequent eating occurrences. it is hypothesized that the liquid food form will elicit weaker dietary compensation; that is, energy intake at other eating events will not be adjusted to compensate for that food. in addition, it is posited that the lower energy food will cause lower compensation postprandially. by having participants consume the same test food daily over a two week learning period, it is thought that they will show improved dietary compensation when the initial testing is repeated due to learned associations between food properties and metabolism.

no expansion provided.

Eligibility criteria:
inclusion criteria: * weight stable (\<3 kg weight change within last 3 months) * constant habitual activity patterns (no deviation \> 1x/wk at 30 min/session within last 3 months) * constant habitual diet patterns within last 3 months * willingness to eat a chocolate-flavored snack at test sessions and two week training period * no allergies to any test foods * not planning to change use of medications known to influence appetite or metabolism * not diabetic * no history of gi pathology * non-smoker for one year or more exclusion criteria:

Keywords: obesity energy intake appetite food form beverage learning dietary compensation
painsquad+: a smartphone app to support real-time pain management for adolescents with cancer

Conditions: Therapy-Associated Cancer

Summary: adolescents with cancer (awc) are in a unique developmental stage that may mean pain characteristics, the impact of pain, and pain treatment outcomes are different in adolescents compared to children and adults. in response, we will develop and test the painsquad+ pain management smartphone app. first, we will conduct usability testing to refine painsquad+ so that it is useable, acceptable and understandable for awc. secondly we will: (a) test the feasibility of conducting a large-scale painsquad+ experiment and (b) begin to examine how effective painsquad+ is at helping adolescents manage pain. we hope that once developed and tested for effectiveness, painsquad+ will improve pain treatment and ultimately quality of life in awc.

using a conservative estimate of 7 adolescents per cycle and 3 testing cycles, 21 adolescents will take part in usability testing of the painsquad+ prototype. recruitment will be conducted in a single hematology/oncology division of a metropolitan and university-affiliated pediatric tertiary care center in toronto, canada. this site hosts one of the largest cancer programs in north america, with approximately 350 new diagnoses each year. based on our previous research at this site, 72 ± 4% (m ± sd; range = 67-75%) of eligible awc agreed to participate in similar studies (unpublished data). convenience sampling will be used to recruit eligible individuals. the testing procedures will commence after eligibility is assessed, informed consent is obtained, and demographic and baseline outcome data are collected. inclusion criteria will be: (a) aged 12-18 years, (b) able to speak and read english, (c) actively undergoing cancer treatment on an in- or out-patient basis, (d) being at least 3 months from diagnosis and (d) having self-reported pain of any intensity in the week immediately prior to recruitment. exclusion criteria will be: (a) one or more major co-morbid (medical or psychiatric) conditions that would preclude use of a smartphone, and (b) palliative/end-of-life patients.

Eligibility criteria:
inclusion criteria: * aged 12-18 years, * able to speak and read english * actively undergoing cancer treatment on an in- or out-patient basis * being at least 3 months from diagnosis * having self-reported pain of any intensity in the week immediately prior to recruitment exclusion criteria: * one or more major co-morbid (medical or psychiatric) conditions that would preclude use of a smartphone * palliative/end-of-life patients.